(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Florida has quietly become America's execution capital - 2Instructions to Distinguish the Wellbeing Dangers Related with 5G Pinnacles
- 3Select Your Definitive Pizza Decision
- 4Experiences in Natural life Protection: Individual Progressives' Excursions
- 5Favored Organic product for Seniors' Prosperity: Make Your Determination
- Climate leaders are talking about 'overshoot' into warming danger zone. Here's what it means
- Supreme Court case about ‘crisis pregnancy centers’ highlights debate over truthful advertising standards
- What you need to know about Trump accounts as Michael and Susan Dell donate $6 billion to the new early childhood investment program
- Wizz CEO: We’re going to invest $1 b. in Israeli market
- FDA official discusses potential link between COVID-19 vaccines and pediatric deaths
- Most loved Amusement Park Firecrackers Show: Which One Lights Up Your Evening?
- Vacation destinations in America
- 6 Web-based Course Stages for Successful Learning and Educating
- Creative Tech Contraptions That Will Work on Your Life
